In a young to middle‑aged woman with hypertension secondary to renal artery stenosis from fibromuscular dysplasia, should treatment be balloon angioplasty alone or include stent placement?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Renal Artery Stenosis from Fibromuscular Dysplasia

For renal FMD, perform balloon angioplasty alone as first-line treatment, reserving stent placement only for bailout situations such as dissection or inadequate balloon result. 1

Primary Treatment Strategy

Balloon angioplasty without stenting is the definitive treatment of choice for symptomatic renal artery stenosis caused by fibromuscular dysplasia. 1 This represents a Class I recommendation with Level B evidence from both ACC/AHA and ESC guidelines. 1

Why Balloon-Only for FMD

The pathophysiology of FMD differs fundamentally from atherosclerotic disease—FMD lesions are non-inflammatory, non-atherosclerotic arterial abnormalities that respond well to mechanical dilation alone. 1 Unlike atherosclerotic ostial lesions that are prone to elastic recoil and require stenting, FMD lesions typically maintain patency after balloon angioplasty. 1

When to Use Bailout Stenting

Stent placement should be considered only in two specific scenarios: 1, 2

  • Arterial dissection occurring during balloon angioplasty
  • Suboptimal angioplasty result with persistent hemodynamically significant stenosis despite adequate balloon inflation

This bailout stenting strategy is explicitly recommended by both ACC/AHA and ESC guidelines. 1

Technical Considerations

Balloon Technique

FMD lesions often demonstrate considerable resistance to dilation, frequently requiring maximum balloon inflation pressures (up to 10 atmospheres). 3 Some focal FMD stenoses may show persistent waisting of the balloon even at maximum inflation. 3

Procedural Success Rates

Meta-analysis data shows that balloon angioplasty for FMD achieves: 4

  • Hypertension cure in 46% of patients (using study-specific definitions)
  • Hypertension cure in 36% using current strict definitions (BP <140/90 mmHg off medications)
  • Major complication rate of only 6.3%
  • Mortality rate of 0.9%

These outcomes are substantially better than the complication profile of surgical revascularization (15.4% major complications, 1.2% mortality). 1, 4

Critical Distinction from Atherosclerotic Disease

This recommendation applies specifically to FMD—do not confuse with atherosclerotic renal artery stenosis, which requires a completely different approach. 1

For atherosclerotic ostial lesions, primary stenting is indicated because: 1

  • Balloon angioplasty alone has only 63% procedural success versus 90% with stenting
  • Restenosis occurs in 48% with balloon alone versus 14% with stenting
  • Aorto-ostial atherosclerotic plaques are prone to elastic recoil

Common Pitfalls to Avoid

Never use primary stenting for FMD lesions—this adds unnecessary hardware, cost, and potential long-term complications without improving outcomes. 1, 2 The single case report suggesting primary stenting 5 contradicts all major guideline recommendations and should not influence practice.

Do not assume all "beaded" renal arteries require intervention—only treat symptomatic FMD with signs of organ ischemia (uncontrolled hypertension, declining renal function). 1, 2

Ensure procedures are performed in experienced centers due to technical complexity and the need for appropriate bailout strategies. 1, 2

Surgical Revascularization

Reserve open surgical reconstruction only for: 1, 2

  • Complex aneurysms associated with FMD
  • Lesions involving arterial bifurcations or multiple segmental vessels
  • Failed endovascular therapy
  • Ex vivo reconstruction for complex disease

In patients under 21 years, prefer internal iliac artery grafts over vein grafts to avoid late aneurysmal degeneration. 1

Adjunctive Medical Therapy

All patients with renal FMD require: 6, 2

  • Antiplatelet therapy (aspirin or clopidogrel)
  • Antihypertensive medications (calcium channel blockers, thiazide diuretics)
  • ACE inhibitors/ARBs can be used in unilateral stenosis with careful monitoring
  • Statin therapy for cardiovascular protection

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Fibromuscular Dysplasia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Primary stenting for renal fibromuscular-dysplastic stenosis: a case report.

European review for medical and pharmacological sciences, 2009

Guideline

Initial Treatment Approach for Renovascular Hypertension

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the best management approach for a young to middle-aged female patient with Fibromuscular Dysplasia (FMD), presenting with Hypertension (elevated blood pressure) and an audible bruit?
Can a CT (Computed Tomography) scan with contrast show fibromuscular dysplasia-related renal artery stenosis?
What are the cardiovascular manifestations of Fibromuscular Dysplasia (FMD)?
What are the differences in clinical presentation between Fibromuscular Dysplasia (FMD) and Renal Artery Stenosis (RAS)?
What is fibromuscular dysplasia (FMD)?
In a hemodialysis patient with a recent thrombotic event, what is the recommended iron supplementation regimen and monitoring strategy?
What are the benefits and indications for placing a central venous catheter (central line)?
In a hemodialysis patient with a recent thrombotic event, should intravenous iron be given before or after the dialysis session?
For a patient with fasting triglycerides ≥200 mg/dL (especially ≥500 mg/dL) who is already on a statin, how should prescription‑grade omega‑3 fatty acids (e.g., icosapent ethyl or mixed eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA)) be used as first‑line adjunct therapy, including initial dose, titration, monitoring, and next steps if targets are not met?
What is the first‑line pharmacologic treatment for adults with prediabetes, including indications for use, initial dosing, titration, and contraindications?
What is the best practice for HPV testing in male patients, including recommendations for asymptomatic men and high‑risk groups such as men who have sex with men, HIV‑positive, and immunocompromised individuals?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.